Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report)'s share price shot up 0.9% during trading on Tuesday . The company traded as high as $1.12 and last traded at $1.09. 181,605 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 5,081,068 shares. The stock had previously closed at $1.08.
Analysts Set New Price Targets
Separately, D. Boral Capital reissued a "buy" rating and set a $10.00 target price on shares of Tevogen Bio in a report on Tuesday, March 11th.
Get Our Latest Analysis on Tevogen Bio
Tevogen Bio Price Performance
The firm has a 50 day moving average of $1.30 and a 200-day moving average of $1.24.
Insiders Place Their Bets
In other news, insider Neal Flomenberg sold 232,968 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $1.09, for a total transaction of $253,935.12. Following the completion of the sale, the insider now owns 3,595,608 shares in the company, valued at approximately $3,919,212.72. This represents a 6.08 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 406,510 shares of company stock valued at $446,763 over the last ninety days. Corporate insiders own 56.60% of the company's stock.
Institutional Investors Weigh In On Tevogen Bio
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of Tevogen Bio in the fourth quarter valued at approximately $38,000. JPMorgan Chase & Co. lifted its position in Tevogen Bio by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock worth $40,000 after acquiring an additional 16,695 shares during the last quarter. Geode Capital Management LLC lifted its position in Tevogen Bio by 31.2% during the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock worth $465,000 after acquiring an additional 107,566 shares during the last quarter. Barclays PLC boosted its holdings in Tevogen Bio by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after acquiring an additional 12,847 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Tevogen Bio in the fourth quarter valued at about $55,000.
Tevogen Bio Company Profile
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
See Also
Before you consider Tevogen Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.
While Tevogen Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
